MIDAS is proud to work with Seda on their expansion to Stockport in a landmark event for the life sciences sector. Andy Burnham, Mayor of Greater Manchester, Inaugurates Seda’s New State-of-the-Art GMP Facility, Projected to Generate 100 Jobs and Boost UK Life Sciences Sector Cheadle (Stockport), Greater Manchester.
In a significant milestone for the North’s life sciences sector, Andy Burnham, Mayor of Greater Manchester, officially opened Seda Group’s new state-of-the-art drug product GMP (Good Manufacturing Practice) facility. The event was marked by a tour of the cutting-edge site, where Andy was accompanied by Labour MP for Waddon, Councillor Rowenna Davis. This new facility promises to enhance Greater Manchester’s reputation as a hub for life sciences innovation and is expected to create up to 100 high-skilled jobs over the next five years, with more than half of its projected revenue coming from international clients.
Andrea Winders, Head of Life Sciences at MIDAS, said:
"At MIDAS, we're proud to support innovative businesses like Seda that are transforming Greater Manchester's life sciences landscape. This £8 million facility represents more than just a local investment - it's a strategic milestone that will generate up to 100 high-skilled jobs, attract international clients, and position Manchester as a global hub for pharmaceutical innovation. By supporting Seda's expansion in Cheadle, we're helping to drive economic growth, enhance the region's scientific capabilities, and showcase the incredible potential of our local life sciences ecosystem."
The newly established division, Seda Clinical Manufacturing Services (CMS), complements Seda’s existing Pharmaceutical Development Services (PDS) arm, expanding into GMP manufacturing, testing, and supply. The facility enables Seda to supply investigational medicinal products for testing in clinical studies by their global biotech client partners.
"We are thrilled to expand our capabilities with the launch of Seda CMS, enhancing our support for both domestic and international clients," said Dr. Paul Stott, CEO. "This facility not only generates jobs and revenue but also reinforces the North of England’s role as an innovation hotspot."
Located adjacent to Seda Pharmaceutical Development Services (PDS), this expansion builds on nearly a decade of success. Founded in 2015, to address a gap in the market for pharmaceutical development integrated with clinical pharmacology, Seda has consistently innovated to meet unmet client needs and growing demand. In 2019, it relocated to state-of-theart labs and offices on Cheadle Royal Business Park and saw substantial growth despite the recent economic climate. This £8 million investment, partially funded by Santander NW, positions Seda to supply drugs for Phase 1 and 2 clinical trials, with its robust order book for GMP manufacturing pending MHRA approval and licensing.
The opening follows Seda’s recognition with the prestigious 2024 King’s Award for Enterprise in International Trade. Drawing ~60% of its revenue from international markets, Seda exemplifies global trade excellence while driving local economic growth.
Mayor Andy Burnham’s presence underscored Manchester’s commitment to fostering innovation. "This facility serves to support the local and UK Life Sciences infrastucture” he noted during the tour.